BENZOCLIDINE

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C14H17NO2
Molecular Weight	231.2903
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O=C(OC1CN2CCC1CC2)C3=CC=CC=C3

InChI

InChIKey=AHKAOMZZTQULDS-UHFFFAOYSA-N

InChI=1S/C14H17NO2/c16-14(12-4-2-1-3-5-12)17-13-10-15-8-6-11(13)7-9-15/h1-5,11,13H,6-10H2

HIDE SMILES / InChI

Description
Sources: http://drdoping.com/instructions/Oxylidin-solution-for-injections/ | http://www.medicus.ru/handbook/drugs/benzoklidin.phtml | https://www.ncbi.nlm.nih.gov/pubmed/4384680

Benzoclidine (Oxylidin) exerts tranquilizing and hypotensive actions. It reduces the excitability of the central nervous system, enhances the effect of hypnotic drugs, analgesics and local anesthetics, has a moderate antihypertensive effect, reduces the excitability of the vasomotor centers, has anti-arrhythmic activity. Benzoclidine is marke indicated for the treatment of anxiety and depression of various origins (particularly mild expressed and associated with cerebrovascular insufficiency), neurosis, personality disorder, cyclothymia, hypertension with cerebral disorders, sinus tachycardia, paroxysmal tachycardia.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
neurological system process 6 Target ID: GO:0050877 Sources: http://drdoping.com/instructions/Oxylidin-solution-for-injections/	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Anxiety 267 Sources: https://www.ncbi.nlm.nih.gov/pubmed/4384745 https://www.ncbi.nlm.nih.gov/pubmed/4384680	Primary	Approved 8429	Benzoclidine Approved Use Anxiety and depression of various origins (particularly mild expressed and associated with cerebrovascular insufficiency), neurosis, personality disorder, cyclothymia, hypertension with cerebral disorders, sinus tachycardia, paroxysmal tachycardia.
Depression 235 Sources: https://www.ncbi.nlm.nih.gov/pubmed/4384745 https://www.ncbi.nlm.nih.gov/pubmed/4384680	Primary	Approved 8429	Benzoclidine Approved Use Anxiety and depression of various origins (particularly mild expressed and associated with cerebrovascular insufficiency), neurosis, personality disorder, cyclothymia, hypertension with cerebral disorders, sinus tachycardia, paroxysmal tachycardia.
Hypertension 567 Sources: https://www.ncbi.nlm.nih.gov/pubmed/4384680	Primary	Approved 8429	Benzoclidine Approved Use Anxiety and depression of various origins (particularly mild expressed and associated with cerebrovascular insufficiency), neurosis, personality disorder, cyclothymia, hypertension with cerebral disorders, sinus tachycardia, paroxysmal tachycardia.

PubMed

Title	Date	PubMed
[ON THE RELATIONSHIP BETWEEN THE HYPOTENSIVE EFFECT OF OXYLIDIN AND ITS EFFECT ON CENTERS OF THE MEDULLA OBLONGATA AND CARDIAC ACTIVITY].	1964 Jan-Feb	14187183
[OXYLIDIN THERAPY OF PATIENTS WITH CEREBROVASCULAR DISEASES WITH MENTAL DISORDERS].	1965	14335737
[CLINICAL TESTING OF OXYLIDIN, A NEW HYPOTENSIVE AGENT, IN THE TREATMENT OF HYPERTENSION].	1965 Feb	14270384
[Experience in the treatment of hypertensive patients with oxylidin under polyclinical conditions].	1965 Nov	4381134
[Oxylidin--a new preparation of tranquilizing and hypotensive action].	1966 Feb	4384680
[The use of oxylidin in psychiatric practice].	1968	4384745
[Chromatographic analysis of aceclidine and oxylidin solutions for injections].	1971 Jan-Feb	4396295
[Antiarrhythmic action of oxylidin].	1973 Apr	4711308
[Effect of antihypertensive compounds on the hypothalamic regulation of baroreceptor reflexes].	1980 Jan-Feb	7379990
[Effect of antihypertensive agents on indices of systemic hemodynamics and baroreceptors reflexes in man].	1981 Jan-Feb	7262303
[Effect of hypotensive preparations on hemodynamics in persons of different sexes and ages].	1982 Nov-Dec	7152000
[Effectiveness of health resort climatic treatment including oxylidin electrophoresis and the correction of the climatic adaptation of patients with the sequelae of viral encephalitis].	1988 Jul-Aug	2973684

Sample Use Guides

In Vivo Use Guide

Average therapeutic dose oral, subcutaneous and intramuscular injection 0.02 - 0.3 grams daily, the duration of treatment 3-8 weeks.

Route of Administration: Other

In Vitro Use Guide

Unknown

Name

Type

Language

BENZOCLIDINE

Official Name

English

3-QUINUCLIDINOL BENZOATE (ESTER)

Common Name

English

3-QUINUCLIDINOL DL-FORM BENZOATE (ESTER) [MI]

Common Name

English

NSC-760346

Code

English

benzoclidine [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29756